Seroprevalence of Pandemic (H1N1) 2009 Influenza and Effectiveness of 2010/2011 Influenza Vaccine During 2010/2011 Season in Beijing, China

Overview

Journal Influenza Other Respir Viruses

Publisher Wiley

Specialty Microbiology

Date 2012 Jan 4

PMID 22212858

Citations 6

Authors

Peng Yang

Li Zhang

Weixian Shi

Guilan Lu

Shujuan Cui

Xiaomin Peng

Daitao Zhang

Yimeng Liu

Huijie Liang

Xinghuo Pang

Quanyi Wang

Affiliations

Soon will be listed here.

Abstract

Background: In the post-pandemic period, pandemic (H1N1) 2009 virus was expected to circulate seasonally and was introduced into trivalent influenza vaccine during 2010/2011 season in the Northern Hemisphere.

Objectives: The aim of this study was to examine the evolution of herd immunity against pandemic (H1N1) 2009 virus in Beijing, China, during 2010/2011 season and effectiveness of the 2010/2011 trivalent vaccine.

Methods: Two serological surveys were conducted before and after 2010/2011 season in Beijing. A case-control study was used to investigate vaccine effectiveness against influenza-like illness (ILI) and lower respiratory tract infection (LRI).

Results: A total of 4509 and 4543 subjects participated in the pre- and post-season surveys, respectively. The standardized seroprevalence of pandemic (H1N1) 2009 influenza increased from 22.1% pre-season to 24.3% post-season (P<0.001). Significant elevation in seroprevalence appeared in the ≥ 60 years age-group (P<0.001), but not in others. The 2010/2011 trivalent vaccine contributed to the higher post-seasonal seroprevalence in unvaccinated individuals (P=0.024), but not in those vaccinated with monovalent pandemic vaccine (P=0.205), as well as in those without prior immunity versus those with immunity. The adjusted effectiveness of the 2010/2011 trivalent vaccine was 79% protection against ILI (95% CI, 61-89%) and 95% against LRI (95% CI: 59-99%).

Conclusions: A slight increase in herd immunity against pandemic (H1N1) 2009 influenza was observed in Beijing, China, during the 2010/2011 season. Prior vaccination and immunity had a suppressive impact on immune response toward this novel influenza virus, elicited by 2010/2011 trivalent vaccine. This trivalent vaccine conferred good protection against ILI and LRI.

Citing Articles

The Occupational Risk of Influenza A (H1N1) Infection among Healthcare Personnel during the 2009 Pandemic: A Systematic Review and Meta-Analysis of Observational Studies.

Lietz J, Westermann C, Nienhaus A, Schablon A PLoS One. 2016; 11(8):e0162061.

PMID: 27579923 PMC: 5006982. DOI: 10.1371/journal.pone.0162061.

What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins.

Vanderven H, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I EBioMedicine. 2016; 8:277-290.

PMID: 27428437 PMC: 4919476. DOI: 10.1016/j.ebiom.2016.04.029.

Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia.

McVernon J, Laurie K, Faddy H, Irving D, Nolan T, Barr I Influenza Other Respir Viruses. 2014; 8(2):194-200.

PMID: 24382379 PMC: 4186467. DOI: 10.1111/irv.12225.

2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos.

Kieffer A, Paboriboune P, Crepey P, Flaissier B, Souvong V, Steenkeste N PLoS One. 2013; 8(4):e61909.

PMID: 23637928 PMC: 3630132. DOI: 10.1371/journal.pone.0061909.

Case-control study of the effectiveness of the 2010-2011 seasonal influenza vaccine for prevention of laboratory-confirmed influenza virus infection in the Korean adult population.

Choi W, Noh J, Seo Y, Baek J, Lee J, Song J Clin Vaccine Immunol. 2013; 20(6):877-81.

PMID: 23576674 PMC: 3675970. DOI: 10.1128/CVI.00009-13.

References

Yu H, Feng Z, Uyeki T, Liao Q, Zhou L, Feng L . Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China. Clin Infect Dis. 2011; 52(4):457-65. PMC: 3060897. DOI: 10.1093/cid/ciq144. View

Co M, Orphin L, Cruz J, Pazoles P, Rothman A, Ennis F . Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine. 2008; 26(16):1990-8. PMC: 2440689. DOI: 10.1016/j.vaccine.2008.02.024. View

Deng Y, Pang X, Yang P, Shi W, Tian L, Liu B . Serological survey of 2009 H1N1 influenza in residents of Beijing, China. Epidemiol Infect. 2010; 139(1):52-8. DOI: 10.1017/S0950268810002189. View

Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer M, Perez-Vilar S, Silvestre-Silvestre E . Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. Vaccine. 2010; 28(47):7460-7. DOI: 10.1016/j.vaccine.2010.09.042. View

Tian L, Shi W, Ying-Deng , Pang X, Peng-Yang , Fang-Huang . Serologic survey of pandemic influenza A (H1N1 2009) in Beijing, China. Prev Med. 2010; 52(1):71-4. DOI: 10.1016/j.ypmed.2010.10.006. View

Zhu F, Wang H, Fang H, Yang J, Lin X, Liang X . A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009; 361(25):2414-23. DOI: 10.1056/NEJMoa0908535. View

Nguyen T, Yuan L, Azevedo M, Jeong K, Gonzalez A, Iosef C . High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen. Clin Vaccine Immunol. 2006; 13(4):475-85. PMC: 1459641. DOI: 10.1128/CVI.13.4.475-485.2006. View

Zeman A, Holmes T, Stamatis S, Tu W, He X, Bouvier N . Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J. 2007; 26(2):107-15. DOI: 10.1097/01.inf.0000253251.03785.9b. View

Pebody R, Hardelid P, Fleming D, McMenamin J, Andrews N, Robertson C . Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Euro Surveill. 2011; 16(6). View

10.

Ortqvist A, Berggren I, Insulander M, de Jong B, Svenungsson B . Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis. 2011; 52(10):1203-11. DOI: 10.1093/cid/cir182. View

11.

Crowe Jr J . Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis. 2001; 33(10):1720-7. DOI: 10.1086/322971. View

12.

Mehr D, Binder E, Kruse R, Zweig S, Madsen R, Popejoy L . Predicting mortality in nursing home residents with lower respiratory tract infection: The Missouri LRI Study. JAMA. 2001; 286(19):2427-36. DOI: 10.1001/jama.286.19.2427. View

13.

Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M . Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010; 375(9720):1100-8. DOI: 10.1016/S0140-6736(09)62126-7. View

14.

Wu J, Xu F, Lu L, Lu M, Miao L, Gao T . Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med. 2010; 363(25):2416-23. DOI: 10.1056/NEJMoa1006736. View

15.

Castilla J, Moran J, Martinez-Artola V, Reina G, Martinez-Baz I, Garcia Cenoz M . Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Euro Surveill. 2011; 16(7). View

16.

Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko D . Immune response to influenza vaccination in a large healthy elderly population. Vaccine. 1999; 17(1):82-94. DOI: 10.1016/s0264-410x(98)00117-0. View

17.

Clark T, Pareek M, Hoschler K, Dillon H, Nicholson K, Groth N . Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med. 2009; 361(25):2424-35. DOI: 10.1056/NEJMoa0907650. View

18.

Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche M, Denis M . Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2009; 375(9708):41-8. DOI: 10.1016/S0140-6736(09)62026-2. View

19.

Wang M, Yuan J, Li T, Liu Y, Wu J, Di B . Antibody dynamics of 2009 influenza A (H1N1) virus in infected patients and vaccinated people in China. PLoS One. 2011; 6(2):e16809. PMC: 3036653. DOI: 10.1371/journal.pone.0016809. View

20.

Crowe Jr J, Firestone C, Murphy B . Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol. 2001; 167(7):3910-8. DOI: 10.4049/jimmunol.167.7.3910. View